Spots Global Cancer Trial Database for thymic carcinoma
Every month we try and update this database with for thymic carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | NCT02062632 | Esophageal Carc... Hypopharyngeal ... Laryngeal Carci... Lymphoma Mesothelioma Metastatic Mali... Metastatic Mali... Metastatic Mali... Non-Small Cell ... Sarcoma Small Cell Lung... Thymic Carcinom... Thymoma Thyroid Gland C... | Doxepin Hydroch... Placebo Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | NCT02623127 | Thymic Carcinom... | Sunitinib | 20 Years - | Seoul National University Hospital | |
| A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | NCT01100944 | Thymoma Thymic Carcinom... | PXD101with cisp... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | NCT01025089 | Thymoma Thymic Carcinom... Clinical Masaok... | Cetuximab, Cisp... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors | NCT02636556 | Thymoma and Thy... | concurrent chem... | 18 Years - 75 Years | Fudan University | |
| A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | NCT01364727 | Thymoma Thymus Cancer Thymic Carcinom... | Amrubicin | 18 Years - | Stanford University | |
| KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | NCT04469725 | Thymic Carcinom... | KN046 | 18 Years - | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | NCT03076554 | Thymoma Thymic Carcinom... | Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors | NCT06301945 | Thymic Epitheli... Thymic Carcinom... Thymoma Thymoma and Thy... | Artificial Inte... Recurrence Pred... | - | Erasmus Medical Center | |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | NCT03583086 | Thymic Carcinom... Non-small Cell ... Refractory Thor... Small-Cell Lung... | Vorolanib Nivolumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Molecular Analysis and Treatment Options of Thymic Malignancies | NCT05667948 | Thymic Epitheli... Thymic Carcinom... Thymic Cancer | Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
| Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | NCT01025089 | Thymoma Thymic Carcinom... Clinical Masaok... | Cetuximab, Cisp... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | NCT04925947 | Thymic Carcinom... | KN046 | 18 Years - | Weill Medical College of Cornell University | |
| A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | NCT01100944 | Thymoma Thymic Carcinom... | PXD101with cisp... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | NCT06248515 | Thymoma Thymic Carcinom... | Sacituzumab gov... | 18 Years - | Georgetown University | |
| First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) | NCT05832827 | Untreated Advan... | MK-3475 Lenvatinib Carboplatin Paclitaxel | 18 Years - | National Cancer Center, Japan | |
| Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | NCT00010257 | Thymoma Thymic Carcinom... | carboplatin paclitaxel | 18 Years - | Eastern Cooperative Oncology Group | |
| Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy | NCT02307500 | Pancreas Cancer Ovarian Cancer Melanoma Sarcoma Thymoma Type B3 Thymoma Type B2 Thymic Carcinom... | Regorafenib | 18 Years - | Istituto Clinico Humanitas | |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors | NCT03102320 | Neoplasms | Cisplatin Gemcitabine Anetumab ravtan... | 18 Years - | Bayer | |
| Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | NCT00589290 | Thymoma Thymic Carcinom... | Belinostat (PDX... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Preoperative Treatment of Patients With High Risk Thymoma | NCT00387868 | Thymoma | cisplatin and e... Surgical Resect... Concurrent Radi... | 18 Years - | Valley Health System | |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | NCT03134118 | Thymoma Type B3 Thymic Carcinom... | Nivolumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | NCT01011439 | Thymic Carcinom... | Milciclib Malea... | 18 Years - | Tiziana Life Sciences LTD | |
| Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | NCT06402708 | Thymic Carcinom... | Chemotherapy Radiotherapy | 18 Years - 75 Years | Fudan University | |
| Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | NCT00589290 | Thymoma Thymic Carcinom... | Belinostat (PDX... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma | NCT00314873 | Thymic Carcinom... | Gleevec (imatin... | 18 Years - | Indiana University | |
| Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | NCT01143545 | Lung Cancer Esophageal Canc... Malignant Pleur... Sarcoma Thymic Carcinom... | Allogeneic Tumo... Celecoxib cyclophosphamid... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) | NCT03449173 | Type B3 Thymoma Thymic Carcinom... | Sunitinib | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer | NCT03170804 | Thyroid Nodule Thyroid Cancer Thyroid Disease... Thymic Carcinom... | 16 Years - | Aventura Hospital and Medical Center | ||
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | NCT03463460 | Thymic Carcinom... | Laboratory Biom... Pembrolizumab Sunitinib Malat... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Molecular Analysis of Thoracic Malignancies | NCT01385722 | Thymus Cancer Thymoma Thymic Carcinom... Lung Cancer Carcinoma, Non-... Mesothelioma | 18 Years - | Stanford University | ||
| Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | NCT01011439 | Thymic Carcinom... | Milciclib Malea... | 18 Years - | Tiziana Life Sciences LTD | |
| Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma | NCT04554524 | Thymoma and Thy... | Chemotherapy+Pe... | 18 Years - | Tang-Du Hospital | |
| Molecular Analysis of Thoracic Malignancies | NCT01385722 | Thymus Cancer Thymoma Thymic Carcinom... Lung Cancer Carcinoma, Non-... Mesothelioma | 18 Years - | Stanford University | ||
| Paclitaxel and Cisplatin for Thymic Neoplasm | NCT00818090 | Thymoma Thymic Carcinom... | paclitaxel and ... | 18 Years - | Korean Cancer Study Group | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | NCT03583086 | Thymic Carcinom... Non-small Cell ... Refractory Thor... Small-Cell Lung... | Vorolanib Nivolumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Paclitaxel and Cisplatin for Thymic Neoplasm | NCT00818090 | Thymoma Thymic Carcinom... | paclitaxel and ... | 18 Years - | Korean Cancer Study Group | |
| Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | NCT02364076 | Thymic Carcinom... Thymus Neoplasm... Thymus Cancer | Pembrolizumab Epacadostat | 18 Years - | Georgetown University | |
| Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) | NCT03921671 | Thymic Carcinom... Thymoma | Ramucirumab | 18 Years - 100 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Study on Proton Radiotherapy of Thymic Malignancies | NCT04822077 | Cardiotoxicity Pulmonary Toxic... Thymus Neoplasm... | Proton radiatio... | 18 Years - | Swedish Lung Cancer Study Group | |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors | NCT03102320 | Neoplasms | Cisplatin Gemcitabine Anetumab ravtan... | 18 Years - | Bayer | |
| Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | NCT01011439 | Thymic Carcinom... | Milciclib Malea... | 18 Years - | Tiziana Life Sciences LTD |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
